Georgia's Online Cancer Information Center

Find A Clinical Trial

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Status
Active
Cancer Type
Prostate Cancer
Unknown Primary
Trial Phase
Phase I
Eligibility
18 Years and older, Male
Study Type
Treatment
NCT ID
NCT04428788
Protocol IDs
CC-94676-PCA-001 (primary)
NCI-2020-13275
U1111-1251-9174
Study Sponsor
Celgene

Summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy
of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Eligibility

  1. Must have histologically or cytologically confirmed adenocarcinoma of the prostate
  2. Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.